Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175758 | 0.84 | COPS5 (0.39) | CYP1A2CYP2C9NPC1CYP2C19RAB9A | |
| SCHEMBL12101006 | 0.80 | RXFP1 (0.38) | CYP1A2CYP2C9NPC1CYP2C19RAB9A | |
| SCHEMBL26564430 | 0.80 | CYP1A2 (0.34) | CYP1A2CYP2C9GAARXFP1 | |
| SCHEMBL12292842 | 0.78 | COPS5 (0.44) | CYP1A2NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17865363 | 0.78 | HCRTR2 (0.38) | CYP1A2CYP2C9GAARXFP1ALDH1A1 | |
| SCHEMBL23682669 | 0.76 | GFER (0.36) | CYP1A2CYP2C9NPC1CYP2C19RAB9A | |
| SCHEMBL23815725 | 0.72 | SHMT2 (0.39) | CYP1A2CYP2C9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27830241 | 0.69 | L3MBTL1 (0.33) | CYP1A2CYP2C9NPC1CYP2C19RAB9A | |
| SCHEMBL10252488 | 0.68 | GAA (0.53) | CYP1A2CYP2C9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2140521 | 0.68 | PTGER1 (0.35) | CYP1A2CYP2C9NPC1CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | CYP1A2 706/4885CYP2C9 1756/4885NPC1 3311/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | CYP1A2 706/4885CYP2C9 1756/4885NPC1 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.